At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Sunitinibdrug
Likely dose
Sunitinib 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Of Sunitinib In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors
In Brief
A Phase 2 clinical trial evaluating Sunitinib for Pancreatic Neuroendocrine Tumors. Completed, enrolled 12 participants across 4 sites.
Detailed Summary
The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Neuroendocrine Tumors
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJul 2010
Primary CompletionJul 2011
Study CompletionNov 2013
TodayJul 2026
First PostedMay 12, 2010
Enrollment StartJul 1, 2010
Primary CompletionJul 1, 2011
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.1 years ago
Interventions
Sunitinibdrug
Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)